- Home
- PULM vs DYAI Comparison
PULM vs DYAI Comparison
Compare PULM & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- DYAI
- Stock Information
- Founded
- PULM 2003
- DYAI 1979
- Country
- PULM United States
- DYAI United States
- Employees
- PULM N/A
- DYAI N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PULM Health Care
- DYAI Health Care
- Exchange
- PULM Nasdaq
- DYAI Nasdaq
- Market Cap
- PULM 33.2M
- DYAI 29.6M
- IPO Year
- PULM N/A
- DYAI 2004
- Fundamental
- Price
- PULM $6.56
- DYAI $0.93
- Analyst Decision
- PULM
- DYAI Strong Buy
- Analyst Count
- PULM 0
- DYAI 1
- Target Price
- PULM N/A
- DYAI $6.00
- AVG Volume (30 Days)
- PULM 60.4K
- DYAI 60.7K
- Earning Date
- PULM 08-12-2025
- DYAI 08-12-2025
- Dividend Yield
- PULM N/A
- DYAI N/A
- EPS Growth
- PULM N/A
- DYAI N/A
- EPS
- PULM N/A
- DYAI N/A
- Revenue
- PULM $1,921,000.00
- DYAI $3,554,344.00
- Revenue This Year
- PULM N/A
- DYAI $22.56
- Revenue Next Year
- PULM $134.88
- DYAI $30.95
- P/E Ratio
- PULM N/A
- DYAI N/A
- Revenue Growth
- PULM N/A
- DYAI 57.59
- 52 Week Low
- PULM $1.78
- DYAI $0.91
- 52 Week High
- PULM $10.40
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- PULM 40.87
- DYAI 41.84
- Support Level
- PULM $6.51
- DYAI $0.91
- Resistance Level
- PULM $6.96
- DYAI $1.06
- Average True Range (ATR)
- PULM 0.89
- DYAI 0.06
- MACD
- PULM -0.13
- DYAI 0.00
- Stochastic Oscillator
- PULM 42.38
- DYAI 15.33
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.